US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 0.749
- +0.017+2.36%
Trading Jul 22 10:09 ET
13.51MMarket Cap-805P/E (TTM)
0.750High0.720Low22.32KVolume0.750Open0.732Pre Close16.42KTurnover0.17%Turnover RatioLossP/E (Static)18.04MShares2.33052wk High-1.93P/B9.80MFloat Cap0.40052wk Low--Dividend TTM13.09MShs Float8.180Historical High--Div YieldTTM4.09%Amplitude0.400Historical Low0.735Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
NeuroSense Therapeutics Stock Forum
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. ...
Neurosense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living With ALS: The Promising Results From the 12-Month Paradigm Study Highlight Primec's Potential as a Disease Modifying Drug
No comment yet